[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 35910
1. Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984". Mol Ther; 2009 Jul;17(7):1302

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28178478.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Published Erratum
  • [Publication-country] United States
  •  go-up   go-down


2. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • PURPOSE: The aim of the study was to analyze early effects and toxicity of salvage high dose rate brachytherapy for local recurrences of adenocarcinoma of the prostate after external beam radiotherapy (EBRT).
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • Only in two patients grade 1 toxicity for rectum was observed.
  • In one patient grade 2 rectal toxicity was observed, and one had urethral stricture.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


3. Reiffel JA: The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum. J Atr Fibrillation; 2008 Dec;1(4):110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28496599.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Lemaître L, Villers A, Mouton D, Puech P: [Transrectal ultrasound and biopsy of the prostate]. J Radiol; 2006 Feb;87(2 Pt 2):201-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal ultrasound and biopsy of the prostate].
  • [Transliterated title] Echographie et biopsies de prostate.
  • This review describes the transrectal ultrasound (TRUS) features of prostate cancer (PC), discusses the role of TRUS in the detection of PC and defines the modalities of biopsies in patients with suspected PC, particularly concerning prevention of complications, the number of biopsies and the biopsy schemes ensuring an optimal cancer detection rate.
  • TRUS alone has limited potential to identify PC because of frequent multifocality of cancer within the prostate, the variable sonographic appearance of prostatic tumors, the poor specificity of focal US abnormalities, and the substantial percentage of isoechoic PC.
  • However, limitations in cancer detection have been appreciated, particularly a false-negative rate approaching 20%.
  • This high failure rate has led investigators to refine biopsy techniques to improve cancer detection and to increase the total number of cores.
  • Currently, recommendations include increasing the biopsy number to a minimum of 10-12 cores, including sampling of the lateral prostate.
  • Refinements in imaging technologies (power Doppler sonography, microbubble intravenous sonographic contrast agents, and MR spectroscopy or dynamic contrast MR imaging) should eventually improve targeting of prostate needle biopsy and reduce false-negative biopsies.
  • [MeSH-major] Biopsy / methods. Prostate / pathology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography
  • [MeSH-minor] Clinical Protocols. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / ultrasonography. Prostatitis / ultrasonography

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484945.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 15
  •  go-up   go-down


5. King RP, Anderson RS, Kandagatla KK: Comment on "Quantifying the interplay effect in prostate IMRT delivery using a convolution-based method" [Med. Phys., - (2008)]. Med Phys; 2008 Dec;35(12):5955-5956

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comment on "Quantifying the interplay effect in prostate IMRT delivery using a convolution-based method" [Med. Phys., - (2008)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28525125.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Conformal radiation treatment / Dose-volume analysis / Dosimetry / Dosimetry/exposure assessment / Dynamic wedges / Intensity modulated radiation therapy / Medical imaging / Medical physics / Medical treatment planning / Philosophy of science / Radiation therapy / Systems analysis / Therapeutic applications, including brachytherapy / Therapeutics / biological organs / cancer / convolution / dosimetry / radiation therapy / telemedicine / tumours
  •  go-up   go-down


6. Lopez S, Simon JM, Mazeron JJ: [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate]. Bull Cancer; 2009 Mar;96(3):261-70
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
  • [Transliterated title] Hormono-radiothérapie des adénocarcinomes non métastatiques de la prostate.
  • Non-metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy.
  • Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormone therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / radiotherapy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Gonadotropin-Releasing Hormone / analogs & derivatives. Humans. Male. Neoplasm Recurrence, Local / prevention & control. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318304.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 40
  •  go-up   go-down


7. Munbodh R, Tagare HD, Chen Z, Jaffray DA, Moseley DJ, Knisely JPS, Duncan JS: 2D-3D registration for prostate radiation therapy based on a statistical model of transmission images. Med Phys; 2009 Oct;36(10):4555-4568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2D-3D registration for prostate radiation therapy based on a statistical model of transmission images.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 American Association of Physicists in Medicine.
  • (PMID = 28525073.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 2D-3D registration / Computed radiography / Computed tomography / Cone beam computed tomography / Digital radiography / Distribution theory and Monte Carlo studies / Gaussian distribution / Medical X-ray imaging / Medical image noise / Medical imaging / Photons / Poisson distribution / Probability theory / Radiography / Registration / Statistical model calculations / Therapeutic applications, including brachytherapy / biological organs / computerised tomography / cone-beam CT / correlation methods / diagnostic radiography / image registration / maximum likelihood / maximum likelihood estimation / medical image processing / phantoms / photon counting / portal images / radiation therapy / setup verification
  •  go-up   go-down


8. Rozet F, Cornu JN, Cussenot O, Fromont G, Hennequin C: [High-risk clinically localised prostate cancer]. Bull Cancer; 2010 Dec;97(12):1517-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-risk clinically localised prostate cancer].
  • [Transliterated title] Cancers de la prostate cliniquement localisés à haut risque de progression.
  • Localized prostate tumors have various clinical, biological and histopathologic characteristics that lead to different progression profiles.
  • High-risk localized prostate tumors have usually a worse outcome, but classic stratification predictive of outcome for prostate cancer is a matter of debate concerning its accuracy.
  • Diagnosis of high-risk prostate cancer has been improved by the use of MRI for local extension and risk of metastases.
  • Recent and major advances in the field of molecular biology are expected to provide new tools to better stratify men with prostate cancer at diagnosis.
  • Indeed, numerous biomarkers are in development, as a consequence of a better comprehension of molecular basis of prostate cancer.
  • New biomarkers (including circulating tumor cells) and genetic variations associated with prostate cancer aggressiveness should help us to define more precisely high-risk disease.
  • [MeSH-major] Neoplasm Recurrence, Local. Prostatic Neoplasms
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Combined Modality Therapy / methods. Drug Resistance, Neoplasm. Humans. Lymph Node Excision / standards. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Neoplastic Cells, Circulating. Positron-Emission Tomography. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy. Radiation Tolerance

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220228.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


9. Hsu SM, Yeh CY, Yeh TC, Hong JH, Tipton AYH, Chen WL, Sun SS, Huang DYC: Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure. Med Phys; 2008 Dec;35(12):5558-5564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure.
  • High dose rate brachytherapy (HDR-BT) is one of the many modalities for prostate cancer treatment.
  • In order to validate a dose verification system for HDR-BT prostate cancer treatment, a radiophotoluminescent glass dosimeter (RPLGD) was used and the measurements were compared with those from a thermoluminescent dosimeter.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28525140.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Annealing / Brachytherapy / Calibration / Cancer / Computed tomography / Dosimetry / Dosimetry/exposure assessment / Medical treatment planning / Monte Carlo N-particle code / Monte Carlo methods / Radiation therapy / Therapeutic applications, including brachytherapy / Thermoluminescent dosimeters / Verification / biology computing / brachytherapy / cancer / dosimetry / high dose rate brachytherapy / patient treatment / prostate cancer / radiophotoluminescent glass dosimeter / thermoluminescent dosimeters
  •  go-up   go-down


10. Processed meat and dairy products linked to prostate cancer. Nurs Stand; 2007 Mar 14;21(27):15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Processed meat and dairy products linked to prostate cancer.
  • : Consumption of processed meat, but not red meat or total meat, is associated with an increased risk of prostate cancer as is a higher intake of dairy products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27958937.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Kim Y, Hsu IJ, Pouliot J, Noworolski SM, Vigneron DB, Kurhanewicz J: Expandable and rigid endorectal coils for prostate MRI: Impact on prostate distortion and rigid image registration. Med Phys; 2005 Dec;32(12):3569-3578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expandable and rigid endorectal coils for prostate MRI: Impact on prostate distortion and rigid image registration.
  • Endorectal coils (ERCs) are used for acquiring high spatial resolution magnetic resonance (MR) images of the human prostate.
  • The goal of this study is to determine the impact of an expandable versus a rigid ERC on changes in the location and deformation of the prostate gland and subsequently on registering prostate images acquired with and without an ERC.
  • Sagittal and axial T2 weighted MR images were acquired from 25 patients receiving a combined MR imaging/MR spectroscopic imaging staging exam for prostate cancer.
  • Both ERCs caused the prostate to tilt anteriorly with an average tilt of 18.5° (17.4±9.9 and 19.5±11.3°, mean±standarddeviation, for expandable and rigid ERC, respectively).
  • However, the expandable coil caused a significantly larger distortion of the prostate as compared to the rigid coil; compressing the prostate in the anterior/posterior direction by 4.1±3.0mm vs 1.2±2.2mm (14.5% vs 4.8%) (p<0.0001), and widening the prostate in the right/left direction by 3.8±3.7mm vs 1.5±3.1mm (8.3% vs 3.4%) (p=0.004).
  • Additionally, the ability to manually align prostate images acquired with and without ERC was significantly (p<0.0001) better for the rigid coil (SI=0.941±0.008 vs 0.899±0.033, for the rigid and expandable coils, respectively).
  • In conclusion, the manual rigid-body alignment of prostate MR images acquired with and without the ERC can be improved through the use of a rigid ERC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28524447.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Antenna arrays / Image analysis / Image registration / MRI / Magnetic resonance imaging / Mechanical and electrical properties of tissues and organs / Medical image spatial resolution / Medical imaging / Medical magnetic resonance imaging / Phased array imaging / Spatial resolution / Ultrasonography / biological organs / biomechanics / biomedical MRI / cancer / coils / expandable endorectal coil / image registration / prostate distortion / rigid endorectal coil / rigid image registration / tumours
  •  go-up   go-down


12. Chibani O, Williamson JF, Todor D: Dosimetric effects of seed anisotropy and interseed attenuation for Pd103 and I125 prostate implants. Med Phys; 2005 Aug;32(8):2557-2566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetric effects of seed anisotropy and interseed attenuation for Pd103 and I125 prostate implants.
  • A Monte Carlo study is carried out to quantify the effects of seed anisotropy and interseed attenuation for Pd103 and I125 prostate implants.
  • Two idealized and two real prostate implants are considered.
  • For clinical pre- and post-procedure implants, the dose to the different structures (prostate, rectum wall, and urethra) is calculated.
  • For all studied cases, LSKS prostate DVHs overestimate D90 by 2 to 5% because of the missing interseed attenuation effect.
  • Finally, effects of seed anisotropy and interseed attenuation must be viewed in the context of other significant sources of dose uncertainty, namely seed orientation, source misplacement, prostate morphological changes and tissue heterogeneity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28523869.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anisotropy / Brachytherapy / Dosimetry / Dosimetry/exposure assessment / Medical imaging / Monte Carlo methods / Phase space methods / Photon scattering / Photons / Tissues / Ultrasonography / biological organs / dosimetry / iodine / palladium / prosthetics
  •  go-up   go-down


13. Wierzbicki M, Schaly B, Osei E, Barnett R: Sci-Thurs PM: Delivery-11: Image guidance for prostate IMRT using low dose cone beam CT. Med Phys; 2008 Jul;35(7Part2):3401

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sci-Thurs PM: Delivery-11: Image guidance for prostate IMRT using low dose cone beam CT.
  • In this work, we address these two issues to enable frequent treatment corrections during a course of prostate intensity modulated radiation therapy (IMRT).
  • These preliminary results show that our automatic local image guidance technique reduces imaging dose and is sufficiently accurate and robust for application in prostate IMRT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512829.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Computed tomography / Cone beam computed tomography / Dosimetry / Image guided radiation therapy / Intensity modulated radiation therapy / Medical imaging / Radiation treatment
  •  go-up   go-down


14. Prostate cancer risk linked to high IGF concentrations. Nurs Stand; 2008 Dec 03;23(13):14-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer risk linked to high IGF concentrations.
  • : High circulating insulin-like growth factor (IGF) concentrations are associated concentrations are associated with a moderately increased risk of prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010363.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Joiner MC, Mogili N, Marples B, Burmeister J: Significant dose can be lost by extended delivery times in IMRT with x rays but not high-LET radiations. Med Phys; 2010 Jun;37(6Part2):2457-2465

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The effect of prolonging the delivery time of a treatment fraction was investigatedin vitro using human PC-3 prostate and HGL21 glioblastoma tumor cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28513910.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Cell cultures / Dosimetry / Dosimetry/exposure assessment / IMRT / Intensity modulated radiation therapy / Neutron radiation effects / Neutrons / Radiation therapy / Radiation treatment / Therapeutic applications, including brachytherapy / X-ray effects / X-ray imaging / X-rays / biological effects of X-rays / biological effects of neutrons / biological organs / cellular effects of radiation / dose protraction / dosimetry / incomplete repair / loss of effectiveness / neutrons / physiological models / radiation therapy / simulation / tumours
  •  go-up   go-down


16. Kyrdalen AE, Hernes E, Fossa SD, Dahl AA: Chronic fatigue in prostate cancer patients after radical prostatectomy (RP) or high-dose radiotherapy (RAD). J Clin Oncol; 2009 May 20;27(15_suppl):5164

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic fatigue in prostate cancer patients after radical prostatectomy (RP) or high-dose radiotherapy (RAD).
  • : 5164 Background: Chronic fatigue (CF) is frequent in cancer patients, but has been less studied in prostate cancer patients (PCPs).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964505.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Gillison TL, Appleman LJ, Friedland DM, Evans TL, Lara PN, Gooding WE, Lenzner DE, Strausser HM, Gingrich JR, Chatta GS: Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e16086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial.
  • : e16086 Background: Docetaxel (D) IV every 21 days, is the only cytotoxic agent that prolongs survival in men with castrate resistant prostate cancer (CRPC).
  • 12 pts had PR (41.4%), 9 had SD (31.0%), and 8 had no response (27.6%) by PSA.
  • For all evaluable pts who had PR or SD by PSA (N = 21), median TTP was 7.1 months (95% CL: 5.5, 9.1 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963108.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Liu S, Schally AV, Xiong S, Cote R, Hawes D, Fazli L, Gleave M, Cai J, Brands F, Engel J, Pinski J: Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists. J Clin Oncol; 2009 May 20;27(15_suppl):5163

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists.
  • : 5163 Background: In the treatment of advanced prostate cancer, the effects of luteinizing hormone releasing hormone (LHRH) agonists are mediated through the down-regulation of pituitary LHRH receptors, inhibiting the pituitary-gonadal axis.
  • Several groups have demonstrated LHRH receptor expression on prostate cancer cells.
  • To date, there is no information on LHRH receptor expression on the prostate after LHRH agonist therapy.
  • (1) 47 men with localized prostate cancer treated with radical prostatectomy with no hormone therapy, (2) 61 men with localized prostate cancer treated with neoadjuvant LHRH agonists for varying duration prior to prostatectomy, and (3) 22 men with metastatic prostate cancer who received a palliative transurethral resection of the prostate after clinical progression.
  • CONCLUSIONS: LHRH receptors are expressed on prostate cancers cells of hormone naïve and castrated patients.
  • The continued expression of these receptors supports the concept of targeting prostatic LHRH receptors to deliver cytotoxic therapy based on LHRH analogs, such as AN-152.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964478.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Olsson H, Attner B, Noreen D, Lithman T: Comorbidity prior to diagnosis in patients with common cancer diagnoses. J Clin Oncol; 2009 May 20;27(15_suppl):e22180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity prior to diagnosis in patients with common cancer diagnoses.
  • : e22180 Background: Chronic disease as diabetes, hypertonia and anemia may be associated with cancer risk as well as affect the short term survival of the malignancy.
  • METHODS: Using population based registry data from specialist and primary care in our health care region comorbidity in the form of anemia, hypertonia, diabetes, rheumatoid arthritis, chronic obstructive pulmonary diasease (KOL), and alcohol related diseases for patients with colon-, rectal-, lung-, prostate and breast cancer and survival were studied.
  • Altogether 2047 colon cancer cases, 985 rectal cancer cases, 2017 lung cancer cases, 3578 breast cancer cases and 5106 prostate cancer cases diagnosed 2000-2005 were included.
  • Comorbidity was studied prior to cancer diagnosis and in order to compare with the general population all first comorbidity diagnoses within 90 days were censored.
  • Patients with colon and rectal cancer had a higher prevalence of anemia, and diabetes.
  • Patients with lung cancer had a higher prevalence of anemia, KOL, diabetes, rheumatoid arthritis for both men and women and for men also a higher prevalence of alcohol related diseases.
  • Except for alcohol related diseases in females with breast cancer comorbidity for the above diseases was not significantly elevated for breast or prostate cancer.
  • Survival of the different cancer diagnoses was not significantly related to the comorbidity except for a tendency of worse survival for patients with alcohol related disease.
  • CONCLUSIONS: The prevalence of some common chronic diseases are elevated especially in colon-, rectal and lung cancer patients.
  • The comorbidity does not seem to affect short term survival of the cancer patient except for alcohol related diagnoses.
  • Our study also indicates the necessity to have all levels of care included in the study base of comorbidity and also emphasizes the need to censor time prior to diagnosis when comparing data with the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963595.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Badalato G, Barlow L, Benson M, McKiernan J: Is age at the time of surgery a predictor of biochemical failure following radical prostatectomy? J Clin Oncol; 2009 May 20;27(15_suppl):e22110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluates the effects of age at surgery on recurrence-free survival in prostate cancer patients at a single institution stratified by established preoperative risk factors.
  • METHODS: Using the Columbia Urologic Oncology Database, a retrospective analysis of 3,736 men treated with open or robotic-assisted laparoscopic radical prostatectomy for prostate cancer from 1988 to 2008 was conducted.
  • In a subset of patients with low-grade cancer (Gleason score 2- 6), advanced age was associated in a univariate analysis with an even greater relative risk of recurrence (HR 1.47, p=0.032).
  • CONCLUSIONS: Older patients who undergo radical prostatectomy for prostate cancer appear to have an increased risk of recurrence, which is most notable in patients with low-grade disease.
  • However, age is not an independent predictor of recurrence when accounting for PSA, grade, and stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963507.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Heiden E, Weiss G, Banez L, Freedland S, Sun L, Hartmann A, van Leenders G, Bangma C, Ittmann M, Wheeler T: PITX2 methylation and biochemical recurrence in postradical prostatectomy prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PITX2 methylation and biochemical recurrence in postradical prostatectomy prostate cancer patients.
  • We previously reported prognostic potential of PITX2 gene promoter methylation for outcome prediction in breast and prostate cancer (PC) patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Fabbri F, Montanari M, Cruciani G, Amadori D, Zoli W: Translational study of the activity of liposomal doxorubicin formulations in hormone-refractory prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational study of the activity of liposomal doxorubicin formulations in hormone-refractory prostate cancer.
  • : e16026 Background: The efficacy of therapy for hormone-refractory prostate cancer (HRPC) is still unsatisfactory and new agents and therapeutic modalities are needed.
  • Toxicity was generally mild, with grade 2 leucopenia and grade 3 neutropenia observed in only 2 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962965.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Yuan J, Orlandi F, Jefferson M, Li H, Gallardo H, Ku G, Wolchok J, Scher H, Allison J, Slovin SF: Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi). J Clin Oncol; 2009 May 20;27(15_suppl):e16149

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi).
  • Recent data [Proc Amer Soc Clin Onc, Abstr#5004, 2008] from castrate metastatic PC pts suggested that Ipi was active but was associated with grade 3 autoimmune adverse events (AEs), such as colitis, hepatitis, hypophysitis or rash, which required high dose steroids.
  • Pts with grade (gd) 0/1/2 tox were termed "low tox" while those with gd 3/4 tox were "high tox".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Nabhan C, Tolzien K, Lestingi TM, Galvez A, Bitran JD: Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC).
  • Secondary end points included the overall clinical benefit calculated as the sum of complete response (CR), partial response (PR), and stable disease (SD), toxicity, and time to disease progression (TTP).
  • Sorafenib was safely combined with chemotherapy with 6 pts experiencing grade 3 fatigue, 3 developing grade 3 hand/foot syndrome, and 1 experiening grade 3 diarrhea.
  • Of these 9 pts (PR+SD), 2 never doubled their PSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG: A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5156

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer.
  • DLT's observed: L2: Grade 4 Neutropenia (1 pt); L3-5 None.
  • Of the 3 patients treated at L6, 2 developed DLTs (febrile neutropeina, grade 4 neutropenia) precluding further dose escalation.
  • Other Grade 3/4 toxicities observed after cycle 1 included deep venous thrombosis (2 pts), grade 3 neutropenia (2 pts), grade 3 facial edema (1 pt) Of 31 pts evaluable for post treatment PSA declines; 8/17 (47%) untreated pts 7/14 (50%) previoustly treated pts had a >50% decline in PSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Cetnar JP, Rosen MA, Vaughn DJ, Haas NB, Troxel AB, Song H, Adluru G, Flaherty KT, O'Dwyer PJ, Amaravadi RK: Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC).
  • Six patients received sorafenib 200mg BID and remaining patients received sorafenib 400 mg BID if <4/6 patients had grade 4 neutropenia.
  • Grade 3 adverse events were neutropenia (77%), hand-foot syndrome (23%), anemia (15%), nausea (8%), and rash (8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Humphreys MR, Ma C, Sridhar SS: Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients.
  • Bivariate Cox Proportional-Hazards regression was used to test the association of age at diagnosis while adjusting for a covariate, with significant covariates entered into multivariate models.
  • Pts <55 and ≥75 presented with advanced stage at diagnosis and progressed to bone metastasis earlier.
  • Pts ≥75 had decreased performance status, more comorbidities, higher PSA at diagnosis, shorter duration of hormone sensitive disease, and were less likely to receive chemotherapy than pts <75.
  • In multivariate analysis with age as a categorical variate, ECOG 3-4 (HR 2.65), time from diagnosis to both HRPC (HR 0.78) and bone metastasis (HR 0.80), and duration of response to androgen ablation (HR 0.86) remained highly predictive.
  • CONCLUSIONS: Age at diagnosis influences OS in HRPC with a bimodal survival curve.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962997.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Saad F, Smith MR, Egerdie B, Tammela TL, Feldman RA, Heracek J, Szwedowski M, Ke C, Leder B, Goessl C: Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):5056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Rice K, Peay K, Hudak J, Elsamanoudi S, Travis J, Lockhart R, Jennifer C, Black L, Hogue S, Brassell S: Factors for choosing prostate cancer treatment and resulting impact on health related quality of life. J Clin Oncol; 2009 May 20;27(15_suppl):9601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors for choosing prostate cancer treatment and resulting impact on health related quality of life.
  • : 9601 Background: The equivalence of surgery (RP), external beam radiation (EBRT), and expectant management (EM) on overall survival of prostate cancer (PCa) patients and their respective impact on health-related quality of life (HRQoL) is controversial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Mizutani Y, Li Y, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Miki T: Significance of the expression of thymidylate synthase in prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16163

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of the expression of thymidylate synthase in prostate cancer.
  • : e16163 Background: Thymidylate synthase ( TS ) is an important enzyme in de novo DNA synthesis pathway.
  • 5-Fluorouracil ( 5-FU ), an anticancer chemotherapeutic agent used clinically against a variety of cancers including prostate cancer, inhibits DNA synthesis by binding TS.
  • In the present study, we examined TS expression in prostate cancer and investigated its prognostic significance.
  • METHODS: Fifty-two prostate cancer tissue specimens were obtained from patients who underwent radical prostatectomy for prostate cancer without neoadjuvant hormonal therapy.
  • Forty-eight prostate cancer tissue specimens were also obtained from patients who underwent radical prostatectomy for prostate cancer with neoadjuvant hormonal therapy.
  • We examined prostate cancer tissue and normal prostate tissue for TS expression by immunohistochemistry.
  • RESULTS: TS was expressed at higher levels in prostate cancer without neoadjuvant hormonal therapy, compared with normal prostate.TS expression in stage T3 prostate cancer was higher than that in stage T2 prostate cancer.
  • In addition, the level of TS expression in Gleason score 7 or greater prostate cancer was higher than that in Gleason score less than 7 prostate cancer.
  • Patients with prostate cancer with negative TS expression without neoadjuvant hormonal therapy had a longer postoperative recurrence-free rate than those with positive expression in the 5 year follow-up.
  • In addition, patients with Gleason score less than 7 prostate cancer with negative TS expression had a much longer postoperative recurrence-free rate than those with positive expression in the 5-year follow-up.
  • TS expression was significantly decreased in prostate cancer patients who received neoadjuvant hormonal therapy, especially stage T2 prostate cancer patients.
  • CONCLUSIONS: The current study has demonstrated for the first time that TS expression may be a prognostic parameterr for prostate cancer patients undergoing radical prostatectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963439.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ross RW, Bankaitis-Davis D, Siconolfi L, Katz L, Storm K, Magidson J, Wassmann K, Oh WK: Sensitivity and specificity of a whole-blood RNA transcript-based diagnostic test for the diagnosis of prostate cancer (CaP) compared with prostate-specific antigen (PSA) alone. J Clin Oncol; 2009 May 20;27(15_suppl):5052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of a whole-blood RNA transcript-based diagnostic test for the diagnosis of prostate cancer (CaP) compared with prostate-specific antigen (PSA) alone.
  • : 5052 Background: Screening for CaP with PSA testing is limited by a high number of false postives, particularly in the setting of benign prostatic hypertrophy (BPH).
  • The goal of this study was to develop whole blood RNA transcript-based diagnostic tests that improve the diagnosis of CaP over PSA alone.
  • Logistic regression methods were used to develop models to optimize prostate cancer diagnosis.
  • Considering only the CaP and normal cohorts, PSA alone (using a cut-off of 4 ng/ml) had a specificity of 94.7%, but sensitivity of only 71.1% for diagnosis of CaP, or 90.8% and 77.6%, respectively, when using age-adjusted PSA criteria.
  • A model consisting of the expression analysis of 6 genes and PSA had a higher specificity (96.1%) and a much improved sensitivity (97.4%) for CaP diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.
  • GRP-receptor overexpression has been detected in cancer cells and, more recently, also in the vascular bed of selected tumors.
  • More information on vascular GRP-receptors in cancer is required to asses their potential for vascular targeting applications.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • RESULTS: Prevalence of vascular GRP-receptors is variable, ranging from 13% (prostate cancer) to 92% (urinary tract cancer).
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Crehange G, Walker PM, Parfait S, Maingon P, Cochet A, Brunotte F, Tizon X, Provent P, Duchamp O: MR-based biomarkers in the diagnosis and the evaluation of the therapeutic response to radiotherapy (ETRR) in prostatic carcinoma (PCa): Implementation of clinical and experimental approaches. J Clin Oncol; 2009 May 20;27(15_suppl):e16136

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR-based biomarkers in the diagnosis and the evaluation of the therapeutic response to radiotherapy (ETRR) in prostatic carcinoma (PCa): Implementation of clinical and experimental approaches.
  • For the pre-clinical study, healthy rat prostate was studied in 3 nude rats.
  • At baseline, healthy prostate shows a low Choline (Cho)/Citrate ratio, whereas the presence of cancer considerably increases this ratio.
  • Although, higher ADC values are normally found in peripheral zone than in central gland, these differences disappear after radiotherapy.
  • In healthy rat prostate high levels of Cho without citrate were noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963351.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Yung RL, Kurth T, Gaziano JM, Driver JA: Cancer aggressiveness and mortality in men of exceptional age. J Clin Oncol; 2009 May 20;27(15_suppl):11051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer aggressiveness and mortality in men of exceptional age.
  • : 11051 Background: Information on the characteristics of cancer in people ≥ 85 is limited, particularly in men.
  • METHODS: We evaluated the type, grade and extent of cancer among the 22,071 men in the Physicians' Health Study by age at diagnosis (dx) (<65, 65-74, 75-84 and ≥85).
  • All cases of cancer, deaths and cause of death were confirmed by medical record review.
  • To investigate the relationship between age at dx and risk of cancer death, we matched newly diagnosed cancer patients to reference subjects by age and a modified Charlson comorbidity score.
  • Prostate cancer remained the most common cancer across all age groups.
  • Melanoma and lung cancer became less common with age, while unknown cancers and gastrointestinal cancers other than colorectal (other GI) became more common.
  • There was no linear trend toward higher or lower grade across the four age groups for individual cancer types.
  • For men ≥ 85 the frequency of metastatic cancer at dx increased for prostate (5.8% vs 14.6% p=0.01) and decreased for other GI tumors (63.8% vs 43.5% p=0.05).
  • Cancer as a cause of death decreased among the entire cohort from 44.1% in men aged 55-64 to 20.5% in men ≥ 85, and among those with cancer it decreased from 93.6% to 52.8%.
  • In the matched cohort analysis, the HR for death from all cancers combined declined markedly across categories of increasing age at cancer dx from 10.9 (95%CI:6.0-19.9) in men < 55 to 1.9 (95%CI:1.5-2.4) in men ≥ 85.
  • There was a similar decline in the HR with increasing age for cancer death from lymphoma, melanoma, prostate and colorectal cancers, whereas the HR of lung, other GI and urinary tumors remained stable.
  • CONCLUSIONS: In this prospective cohort of apparently healthy U.S. male physicians, characteristics of cancer in men ≥ 85 varied considerably with tumor type and may reflect changes in cancer detection or biology with age.
  • Cancer specific mortality decreased markedly with increasing age of diagnosis for most cancers.
  • This is likely explained by competing risks of death which outpace that of cancer, but may also suggest decreased cancer aggressiveness in advanced age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963157.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Hotte SJ, Yu EY, Hirte HW, Higano CS, Gleave M, Chi KN: OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. J Clin Oncol; 2009 May 20;27(15_suppl):3506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3506 Background: Heat shock protein 27 (Hsp27) is a chaperone protein expressed in many cancers and implicated as a therapeutic "hyper-node" affecting multiple pathways in cancer progression.
  • METHODS: Eligible patients (pts) had to have metastatic breast, ovarian, prostate, NSCLC, or bladder cancer.
  • Median age was 62 (range: 33-86) yrs; 16 pts had prostate, 10 breast, 5 ovary and 3 lung ca.
  • More than 80% of pts had grade (Gr) 1/2 infusion reactions during the LDs or C1.
  • Three pts with prostate ca had PSA declines of 43%, 58%, 62% and 3 pts with ovarian cancer had CA-125 declines of 27%, 28%, and 41%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Podder T, Clark D, Sherman J, Fuller D, Messing E, Rubens D, Strang J, Brasacchio R, Liao L, Ng WS, Yu Y: In vivo motion and force measurement of surgical needle intervention during prostate brachytherapy. Med Phys; 2006 Aug;33(8):2915-2922

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo motion and force measurement of surgical needle intervention during prostate brachytherapy.
  • In this paper, we present needle insertion forces and motion trajectories measured during actual brachytherapy needle insertion while implanting radioactive seeds in the prostate glands of 20 different patients.
  • The knowledge gleaned from this study promises to be useful for not only designing mechanical/robotic systems but also developing a predictive deformation model of the prostate and real-time adaptive controlling of the needle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2006 American Association of Physicists in Medicine.
  • (PMID = 28523786.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Brachytherapy / Electromagnetic radiation detectors / Image sensors / Liver / Mechanical and electrical properties of tissues and organs / Position sensitive detectors / Robotics / Skin / Therapeutic applications, including brachytherapy / Tissues / Ultrasonography / biological organs / biomechanics / biomedical equipment / biomedical ultrasonics / brachytherapy / force measurement / in vivo force / motion measurement / needle insertion force / position measurement / prostate brachytherapy / prostate seed implantation / robotic needle intervention / surgical needle insertion
  •  go-up   go-down


37. Abedi M, Ma Q, Bais A, Gomes E, Beaudoin E, Lu L, Davol P, Cohen SI, Junghans R: Phase I trial of anti-PSMA designer T-cell autografting in prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of anti-PSMA designer T-cell autografting in prostate cancer.
  • : e16132 Background: We created chimeric immunoglobulin-T cell receptors (IgTCR) specific for prostate specific membrane antigen (PSMA).
  • When expressed in patient T cells, these "designer T cells" specifically kill prostate cancer cells in vitro and in vivo in animal models, with 5/9 (55%) of xenografted mice experiencing complete remissions (Ma et al.
  • Prostate 2004:61:12-25).
  • A Phase I clinical trial was approved by the FDA in metastatic prostate cancers.
  • CONCLUSIONS: A new approach to adoptive immune therapy in metastatic prostate cancer has been devised.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963366.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Veuillen C, Gravis G, Marcy M, Walz J, Bladou F, Salem N, Brunelle S, Olive D: Alterations of natural killer cells in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of natural killer cells in metastatic prostate cancer.
  • : e16131 Background: Recently, prostate cancer (PCa) has been considered as a potential target for antitumoral immunotherapy and cells such as Natural Killer (NK) cells, with antitumoral activity are a promising candidate.
  • METHODS: Activating and inhibitory receptors were analysed by flow cytometry in peripheral NK cells from 8 patients with metastatic androgen dependent prostate cancer (ADPC), 10 with metastatic androgen independent prostate cancer (AIPC), 7 patients with localized prostate cancer (LPC ) and 15 healthy donors.
  • Moreover, this could constitute a potential mechanism for cancer cells immune escape and a possible target for therapies improving NK functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963371.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Rademacher BL, Garzotto M, Higano CS, O'Brien CA, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM: Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer.
  • : 5121 Background: Efforts to incorporate systemic therapy with activity against castration-resistant prostate cancer into the early management of high-risk disease are motivated by persistent risk of relapse when neoadjuvant androgen suppression therapy (AST) is combined with surgery.
  • As docetaxel and mitoxantrone exert anti-tumor effects through distinct cellular mechanisms, this combination has the potential for synergistic activity against prostate cancer.
  • METHODS: 57 high-risk prostate cancer patients were enrolled in a phase I/II study of weekly docetaxel 35 mg/m<sup>2</sup> and escalating mitoxantrone to 4 mg/m<sup>2</sup> delivered weekly for 3 of every 4 weeks per cycle for 4 cycles over 16 weeks followed by radical prostatectomy.
  • Grade 4 toxicities were limited to leucopenia, neutropenia and hyperglycemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964409.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Crawford ED, Moul J: Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men. J Clin Oncol; 2009 May 20;27(15_suppl):5051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men.
  • : 5051 Background: Recent studies have shown that prostate specific antigen (PSA) values can be used to predict risk of developing prostate cancer (PCa) in the future.
  • The risk of 4-year PCa diagnosis was evaluated based on a 1.5 ng/mL PSA threshold, and was assessed by logistic regression, controlling for age and race.
  • CONCLUSIONS: This analysis validates that men with PSA values 1.5 to 4 ng/mL are at a significantly increased risk for developing future prostate cancer compared to those with a PSA value below the 1.5 threshold.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962957.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Nanda A, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV: Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with radiation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):9543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with radiation therapy.
  • : 9543 Background: To identify clinical factors associated with prostate cancer-specific mortality (PCSM), adjusting for co-morbidity, in elderly men with intermediate-risk prostate cancer treated with brachytherapy alone or in conjunction with external beam radiation therapy (EBRT).
  • METHODS: The study cohort comprised 1,978 men of median age 71 (interquartile range [IQR], 66-75) years with intermediate-risk prostate cancer (Gleason score 7 with PSA 20 ng/mL or less and tumor category T2c or less).
  • CONCLUSIONS: Detection of intermediate-risk prostate cancer in elderly men without CVD at lower PSA levels is associated with a lower risk of PCSM; this risk reduction is not observed in men with known CVD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963605.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Basch EM, Sit L, Fruscione M, Burke L, Kane R, George D, Carducci MA, Matthew P, Beer TM, Scher HI: Pain and analgesic use in men with metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pain and analgesic use in men with metastatic prostate cancer.
  • : e20515 Background: Pain is an important endpoint in metastatic prostate cancer and was the basis for the 1996 FDA approval of mitoxantrone.
  • The prevalence and distribution of pain severity at specific points in the prostate cancer disease continuum are not well defined.
  • METHODS: A questionnaire that includes the Brief Pain Inventory and additional pain/analgesia items was developed as a collaboration between the DOD/PCF-supported Prostate Cancer Clinical Trials Consortium (PCCTC) and FDA Study Endpoints and Labeling Design (SEALD) team.
  • RESULTS: Between August-December 2008, 325 men with prostate cancers representing different disease states being seen in outpatient clinics of participating centers were each queried once.
  • CONCLUSIONS: Pain is sufficiently prevalent in men with metastatic prostate cancer to enable prospective assessment of palliation endpoints in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960916.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA: A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):5135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial.
  • : 5135 Background: ATN-224 (choline tetrathiomolybdate) is an orally active, small molecule that has antiangiogenic and antitumor effects in prostate cancer (PCa) models.
  • ATN-224 was well tolerated with a few reversible Grade 3/4 neutropenia and Grade 3 skin rash (both 4%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Aspirin could have a role in preventing prostate cancer. Nurs Stand; 2010 Oct 20;25(7):16-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin could have a role in preventing prostate cancer.
  • : New research provides further evidence that aspirin may have chemoprotective activity against prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019607.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Tagawa ST, Parmar S, Pena J, Petrillo K, Matulich D, Selzer J, Vallabhajosula S, Goldsmith SJ, Bander NH, Nanus DM: Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Kubicek GJ, Kubicek GJ, Brown S, Redfield S: Combined brachytherapy and external beam radiation for prostate cancer in a community setting. J Clin Oncol; 2009 May 20;27(15_suppl):e16147

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined brachytherapy and external beam radiation for prostate cancer in a community setting.
  • : e16147 Background: Prostate cancer is the most common male malignancy, and there is no one standard treatment modality.
  • One treatment option is the combination of external beam radiotherapy and permanent transperineal brachytherapy seed implant Methods: Retrospective review of prostate cancer and side effect outcomes at a single institution in the community setting.
  • Not including impotence, acute toxicity greater than or equal to Grade 2 was seen in 115 patients (102 GU and 13 GI) and 193 patients had late toxicity greater than or equal to Grade 2 (155 GU and 38 GI).
  • CONCLUSIONS: This is the largest series reporting on the outcome of combination brachytherpay implant and external beam radiation in the treatment of prostate cancer.
  • Combination treatment using brachytherapy and external beam radiation is well tolerated, with a low rate of biochemical failure and should be considered one of the treatment options for prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963422.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Mayer TM, Kelly WK, Concato J, Chao H: Ineligibility of prostate cancer patients in the VA Connecticut Healthcare System (VACHS) to participate in clinical trials due to comorbidities. J Clin Oncol; 2009 May 20;27(15_suppl):5169

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ineligibility of prostate cancer patients in the VA Connecticut Healthcare System (VACHS) to participate in clinical trials due to comorbidities.
  • : 5169 Background: A large proportion of prostate cancer patients receive their care within the VA Healthcare System.
  • Our objective was to quantify the frequency with which castrate resistant prostate cancer (CRPC) patients in VACHS would be excluded from major phase III randomized controlled trials.
  • METHODS: We reviewed records of all prostate cancer patients at the VACHS between 2004-2007 and identified patients with CRPC.
  • We reviewed eligibility criteria of 24 major phase III clinical trials, from 2006 onwards, studying investigational drugs for CRPC and created a "master list" (ML) of the most pertinent criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964499.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kanao K, Shinojima T, Nakashima J, Ohigashi T, Kikuchi E, Miyajima A, Nakagawa K, Oya M: External validation of preoperative nomograms for predicting pathological stage of prostate cancer: Analysis of 716 Japanese cases. J Clin Oncol; 2009 May 20;27(15_suppl):e16078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External validation of preoperative nomograms for predicting pathological stage of prostate cancer: Analysis of 716 Japanese cases.
  • : e16078 Background: For the purpose of predicting pathological stage of prostate cancer, Partin et al have developed preoperative nomograms (Partin Tables).
  • Partin tables were modified and updated twice to reflect a more contemporary condition of prostate cancer stage at diagnosis.
  • Although the characteristics of prostate cancer are thought to vary between Asian and Western patients, there are few studies to validate the prognostic accuracy of Partin tables in Asian patients and there is no study to validate three Partin table simultaneously.
  • PSA at diagnosis was 10.45±0.60 (mean±SE).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963042.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B: Correlation of hypoxic prostate/muscle p&lt;sub&gt;O2&lt;/sub&gt; (P/M P&lt;sub&gt;O2&lt;/sub&gt;) ratio and biochemical failure in patients with localized prostate cancer: Long-term results. J Clin Oncol; 2009 May 20;27(15_suppl):5136

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of hypoxic prostate/muscle p<sub>O2</sub> (P/M P<sub>O2</sub>) ratio and biochemical failure in patients with localized prostate cancer: Long-term results.
  • : 5136 Background: Tumor hypoxia may confer radioresistance in prostate cancer.
  • The purpose of this study was to correlate tumor oxygenation status with long term biochemical outcome following prostate bracytherapy.
  • METHODS: Custom made Eppendorf P<sub>O2</sub> microelectrodes were used to obtain P<sub>O2</sub> measurements from the prostate (P), focused on + biopsy locations, and normal muscle tissue (M), as a control, in the operating room using a sterile technique.
  • A total of 11,516 measurements were obtained in 57 patients with localized prostate cancer immediately prior to prostate brachytherapy.
  • CONCLUSIONS: Hypoxia in prostate cancer (low P/M P<sub>O2</sub> ratio) significantly predicts for poor long term biochemical outcome on multivariate analysis, suggesting that novel hypoxic strategies should be investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Litterman AJ, Yancovitz M, Shapiro R, Berman R, Pavlick A, Daarvishian F, Blank S, Lee P, Osman I, Polsky D: Detection of BRAF kinase mutations in melanoma, ovarian, and prostate carcinomas: Evidence for tumor heterogeneity in clinical samples. J Clin Oncol; 2009 May 20;27(15_suppl):11031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of BRAF kinase mutations in melanoma, ovarian, and prostate carcinomas: Evidence for tumor heterogeneity in clinical samples.
  • METHODS: BRAF MS-PCR and conventional sequencing were performed on DNA from 304 tumors (112 melanoma, 110 ovarian, 82 prostate) to determine the presence of the BRAFV600E hot-spot mutation.
  • RESULTS: DNA sequencing detected mutations in 5/110 (4.5%) ovarian tumors, 1/82 (1.2%) prostate tumors, and 36/112 (32%) melanomas.
  • In contrast, the MS-PCR assay detected mutations in 12/110 (11%) ovarian tumors, 15/82 (18%) prostate tumors and 85/112 (76%) melanomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964001.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Wu Y, Kwok Y, Mirmiran A, Goloubeva O, Mannuel H, Dawson N, Amin P, Hussain A: Weekly paclitaxel (P) with concurrent external beam radiation (EBRT) and androgen deprivation therapy (ADT) in high-risk prostate cancer (PC) patients with or without prior prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel (P) with concurrent external beam radiation (EBRT) and androgen deprivation therapy (ADT) in high-risk prostate cancer (PC) patients with or without prior prostatectomy (RP).
  • Treatment included ADT (4 or 24 mos, preplanned based on clinical presentation), P (40, 50, or 60 mg/m2/wk) x 7 with EBRT, and whole pelvis EBRT 45 Gy with 19.8 Gy boost (total 64.8 Gy) to prostate bed in RP pts and 25.2 Gy boost (total 70.2 Gy) to prostate in LAPC pts.
  • There were no acute grade 4 toxicities.
  • Most common grade 3 toxicities were diarrhea 15%, urinary urgency or incontinence 10%, tenesmus 5%, and leukopenia 3%.
  • CONCLUSIONS: This trial establishes the feasibility of tri-modality therapy with ADT, EBRT and weekly paclitaxel in high risk PC, both in RP pts and in LAPC pts with intact prostate glands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964408.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Hayes M, Reeder C, Beer TM: Acupuncture for hot flashes for prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16125

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acupuncture for hot flashes for prostate cancer patients.
  • : e16125 Background: Hot flashes are a common adverse effect of androgen suppression therapy (AST) for prostate cancer.
  • Further studies of acupuncture for hot flashes in men undergoing hormonal treatment for prostate cancer are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963373.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ponsky LE, Lillibridge C, Brindle J, Zhang Y, Wessels B, Einstein DB: Stereotactic robotic radiosurgery for localized prostate cancer: Initial evaluation of acute toxicities. J Clin Oncol; 2009 May 20;27(15_suppl):e16006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic robotic radiosurgery for localized prostate cancer: Initial evaluation of acute toxicities.
  • : e16006 Background: We evaluated the initial acute toxicities experienced by patients treated with cyberknife fractionated radiosurgery for low and low-intermediate risk prostate cancer.
  • METHODS: Twenty-two patients with low or low-intermediate risk prostate cancer (T2a, GG 3+3=6 or 3+4=7, PSA <10) were enrolled prospectively on an IRB approved protocol and treated the planning target volume (PTV)(prostate+5mm margin) with cyberknife fractionated radiosurgery to a dose of 36.25 Gy in 5 fractions (7.25Gy/fraction).
  • The target volume included the prostate and seminal vesicles.
  • RESULTS: Patients treated on study included 12 with GG 3+3=6 cancer and 10 with GG 3+4=7 cancer.
  • There were 5 grade 1 acute toxicities including (diarrhea, fatigue, mild urinary frequency, hemorrhoid and a rash) and 7 grade 2 toxicities including (bladder spasms, painful urinary, bowel irregularity, rectal pain, urethritis and numbness in the upper thigh), all grade 1 and 2 toxicities resolved within three months of treatment.
  • The one patient with grade 2 thigh numbness was not thought to be study related toxicity.
  • Two patients developed grade 3 toxicity.
  • CONCLUSIONS: Cyberknife fractionated radiosurgery for patients with early stage prostate cancer appears to be safe on our early initial assessment.Continued evaluation and longer follow-up ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962931.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Small E, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, Liu G, Sharib J, Rosenberg J: Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium. J Clin Oncol; 2009 May 20;27(15_suppl):5058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium.
  • These agents were therefore combined in a phase I study which demonstrated anti-cancer activity and defined the recommended phase II dose used in this trial.
  • Grade 3 or 4 neutropenia was seen in 6 pts (17%) and grade 3 or 4 thrombocytopenia was seen in 3 (8%).
  • Nonhematologic grade 3/4 events possibly related to study drug have included grade 3 fatigue (3 pts), grade 3 pneumonia (2 pts), and grade 3 atrial fibrillation, grade 4 myocardial infarction, grade 4 prostatitis, grade 3 nausea/vomiting, grade 3 neuropathy, grade 3 elevated transaminases, grade 3 dizziness, grade 3 dehydration, grade 3 shortness of breath, and grade 4 vasovagal syncope (1 pt each).
  • Grade 2 neuropathy has been seen in 4 patients.
  • This study was supported in part by CTEP/NCI and the DOD Prostate Cancer Clinical Trials Consortium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962970.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Talantov D, Jatkoe T, Bohm M, Zhang Y, Stricker P, Kattan MW, Sutherland RL, Kench JG, Wang Y, Henshall S: Gene-based prediction of PSA recurrence for clinically localized prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-based prediction of PSA recurrence for clinically localized prostate cancer patients.
  • : 5132 Background: Accurate estimates of the risk of recurrence are needed for the optimal management of patients with clinically localized prostate cancer.
  • We combined an established nomogram and novel molecular predictors into a new prognostic model of prostate specific antigen (PSA) recurrence.
  • METHODS: Gene expression profiles from formalin-fixed, paraffin-embedded (FFPE) localized prostate cancer tissues were analysed to identify genes associated with PSA recurrence.
  • CONCLUSIONS: This new gene-based classifier has superior predictive power when compared against the 5-year nomogram to assess risk of PSA recurrence in patients with organ-confined prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964430.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Undevia-Yedavalli N, Dandade N, Luu T, Samaras A, Sartor O, Nonzee N, Bennett C: Quality-of-life and LhRH agonist therapy among prostate cancer patients following PSA failure. J Clin Oncol; 2009 May 20;27(15_suppl):e16083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality-of-life and LhRH agonist therapy among prostate cancer patients following PSA failure.
  • : e16083 Background: Growing numbers of prostate cancer patients experience biochemical relapse (PSA failure) after initial treatment.
  • We evaluated health related quality of life and treatment satisfaction among prostate cancer patients who experience PSA failure.
  • METHODS: Eligibility criteria were receipt of primary therapy for prostate cancer followed by a PSA nadir and subsequent PSA rise to at least 0.2 ng/ml.
  • RESULTS: Castrated versus observed patients who are satisfied with their sexual activity report similar health-related QoL, with the exception of higher rates of maintaining an erection (73.3% vs. 32.0%) and not having prostate cancer affect sexual activity (66.7% vs. 28.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963104.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Poiesz B, Reeves J, McNulty W, Maleski J, Holmlund J, Leopold L: Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer.
  • : 5145 Background: Antiapoptotic Bcl-2 family proteins are overexpressed in castrate resistant prostate cancer (CRPC) and contribute to resistance to therapy.
  • Five pts (24%) with measurable disease had a PR or CR by RECIST criteria and one additional patient had tumor shrinkage of 29%.
  • The grade 3/4 AEs occurring in more than 1 pt were: neutropenia (5), anemia, anorexia, dyspnea and leukopenia (2 pts each).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964445.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Birdsall TC, Cain L, Martin J, Birdsall SM, Wiersum L, Anderson K, Eden B, Flynn J, Kelly D, Braun DP: The effect of naturopathic and nutritional supplement treatment on tumor response, control, and survival in prostate cancer patients treated with radiation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of naturopathic and nutritional supplement treatment on tumor response, control, and survival in prostate cancer patients treated with radiation therapy.
  • : e16088 Background: Potential antagonism of clinical response to cancer treatment by naturopathic/nutritional supplements (NNS) with anti-oxidant activity has been suggested.
  • This study assessed effects of NNS on tumor response to radiation therapy (RT) in prostate cancer patients (PCpts).
  • CONCLUSIONS: This study shows that NNS with antioxidant activity do not interfere with clinical response to RT ± HT as definitive treatment for limited stage prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Kantoff PW, Schuetz T, Blumenstein BA, Glode MM, Bilhartz D, Gulley J, Schlom J, Laus R, Godfrey W: Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).
  • : 5013 Background: Therapeutic poxviral vaccines for prostate cancer are safe with preliminary evidence of clinical benefit in phase I/II studies.
  • PROSTVAC-VF (PV) comprises 2 recombinant viral vectors (Vaccinia and Fowlpox), each encoding transgenes for prostate specific antigen (PSA) and 3 immune costimulatory molecules (B7.1, ICAM-1, and LFA3: TRICOM).
  • These data provide evidence of prolonged anti-tumor activity, but need to be confirmed in a larger phase III study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962903.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Purnell JQ, Palesh O, Mustian K, Peppone L, Morrow G, Colman LK, Lord R, Flynn PJ: Cancer-related self-efficacy in African American prostate cancer patients compared to whites. J Clin Oncol; 2009 May 20;27(15_suppl):5067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-related self-efficacy in African American prostate cancer patients compared to whites.
  • : 5067 Background: African American (AA) men are nearly twice as likely as white (W) men to be diagnosed with prostate cancer.
  • Cancer-related self-efficacy (i.e., confidence in one's ability to manage cancer) has been associated with better physical and psychosocial functioning, but little is known about self-efficacy in African American prostate cancer patients.
  • This study compared AA and W ratings of cancer-related self-efficacy for 308 prostate cancer patients (M age = 66.13, SD = 8.48; 9% AA) who participated in a group therapy intervention.
  • METHOD: Independent groups t-tests were used to determine whether there were significant differences at baseline in mean scores for each group on the Stanford Self-Efficacy Scale (SSE), which asks respondents to rate their confidence in the ability to cope with cancer on a 0-100 scale, with 0 indicating no confidence.
  • CONCLUSIONS: Results suggest that, compared to W men, AA men have less confidence in their ability to cope with prostate cancer following diagnosis.
  • AA men report the least confidence in their ability to cope with the possibility of death as a result of cancer, and they also report less confidence in their ability to focus and relax.
  • They may also have greater difficulty discussing their cancer with family, friends, and healthcare personnel.
  • As cancer-related self-efficacy has been linked to symptom-related and psychological adjustment, interventions targeting self-efficacy in AA prostate cancer patients are needed that are tailored to their unique needs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964250.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Cooperberg MR, Broering JM, Carroll PR: Local variation in primary treatment of localized prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local variation in primary treatment of localized prostate cancer.
  • : 5126 Background: We aimed to characterize and quantify variation in the primary management of localized prostate cancer at the level of clinical practice sites.
  • METHODS: Data were abstracted from patients accrued to the CaPSURE national prostate cancer registry.
  • Descriptive analyses were performed, and a random effects logit hierarchical model was constructed, controlling for year of diagnosis, age, comorbidity, PSA, Gleason score, clinical T stage, and percent of biopsy cores positive, to estimate the proportion of variation in primary treatment selection explicable by practice site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Seibert RM, Ramsey CR, Garvey DR, Hines JW, Robison BH, Outten SS: Verification of helical tomotherapy delivery using autoassociative kernel regressiona). Med Phys; 2007 Aug;34(8):3249-3262

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Delivery sequences from three archived patients (prostate, lung, and head and neck) were used in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2007 American Association of Physicists in Medicine.
  • (PMID = 28523657.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Ancillary equipment / Computed tomography / Dosimetry / General statistical methods / Image guided radiation therapy / Intensity modulated radiation therapy / Low temperature detectors / Lungs / Multileaf collimators / Particle beam detectors / Quality assurance in radiotherapy / Radiation treatment / Record and verify systems and applications / Testing procedures / Wedges and compensators / biological organs / collimators / dosimetry / empirical modeling / kernel regression / lung / phantoms / quality assurance / radiation therapy / regression analysis / sinogram detector data / tomotherapy
  •  go-up   go-down


63. Oliver M, Gladwish A, Craig J, Chen J, Wong E: Incorporating geometric ray tracing to generate initial conditions for intensity modulated arc therapy optimization. Med Phys; 2008 Jul;35(7Part1):3137-3150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The method was applied to two phantom cases, a clinical prostate case and the Radiological Physics Center (RPC)'s head and neck phantom.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28513018.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Collimators / Computed tomography / Dosimetry / Dosimetry/exposure assessment / Intensity modulated radiation therapy / Linear accelerators / Monte Carlo methods / Multileaf collimators / Optimization / Photon scattering / Ray tracing / Signal generators / collimators / dosimetry / initial conditions / intensity modulated arc therapy / optimisation / optimization / phantoms / prior information / radiation therapy / ray tracing
  •  go-up   go-down


64. Howell DD, James JL, Hartsell WF, Suntharalingam M, Machtay M, Suh JH, Demas WF, Sandler HM, Kachnic LA, Berk LB: Randomized trial of short-course versus long-course radiotherapy for palliation of painful vertebral bone metastases: A retrospective analysis of RTOG 97-14. J Clin Oncol; 2009 May 20;27(15_suppl):9521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9521 Background: RTOG 97-14 [Hartsell et al, breast/prostate cancer patients (pts) with painful bone metastases randomized to 8 Gy/1 fraction or 30 Gy/10 fractions], revealed no difference in pain relief or narcotic use 3 months post randomization.
  • There were significant differences in acute grade 2-4 toxicityand acute grade 2-4 GI toxicity [6% vs. 14%, p=0.01] at 3 months, lower toxicity seen in 8 Gy.
  • Late toxicity was rare, with 1 grade 3 CNS event (8 Gy) and 1 grade 4 lung event (30 Gy).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964506.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB: Scintigraphic evaluation of mandibular bone turnover inhibition by bisphosphonates in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):9519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with skeletal metastases from a solid tumor (n=40) were individually matched with cancer patients without BP exposure (n=40) and controls with neither a malignancy nor BP use (n=40).
  • Malignancies included: breast (n=30), prostate (n=4), colon (n=2) and bladder cancer (n=2); and neuroendocrine carcinoma (n=2).
  • The mean MBT was significantly lower in BP using cancer patients (2.59) compared with matched controls from oncological patients without BP use 3.01 (difference 0.42; 95% CI 0.13 - 0.72; p=0.006), or patients without cancer or BP exposure 3.09 (difference 0.50; 95% CI 0.21 - 0.78; p=0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964493.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Thayer S, Cooke J, Kaura S: A retrospective database analysis to assess the impact of zoledronic acid (ZOL) on skeletal-related events (SREs) in solid tumor cancer and multiple myeloma (MM) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):9518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective database analysis to assess the impact of zoledronic acid (ZOL) on skeletal-related events (SREs) in solid tumor cancer and multiple myeloma (MM) patients (pts).
  • : 9518 Background: For cancer pts with malignant bone lesions (BM), SREs including pathologic fracture, spinal cord compression, hypercalcemia of malignancy, and radiotherapy and/or surgery to bone are associated with significant morbidity and mortality and reduced quality of life.
  • Pts older than 18 years with solid tumors (breast, prostate, lung, bladder, or renal cell cancers) or MM and BM diagnosed between Jan 2001 and Dec 2006 were included.
  • CONCLUSIONS: This study showed that in cancer pts with BM, persistence with ZOL resulted in reduced risk of developing first and subsequent SREs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964490.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Launay-Vacher V, Janus N, Spano J, Gligorov J, Ray-Coquard I, Beuzeboc P, Morere J, Pourrat X, Deray G, Oudard S: Impact of renal insufficiency on cancer survival: Results of the IRMA-2 study. J Clin Oncol; 2009 May 20;27(15_suppl):9585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of renal insufficiency on cancer survival: Results of the IRMA-2 study.
  • : 9585 Background: Data are scant on the potential impact of renal insufficiency (RI) on the morbidity and mortality of cancer patients.
  • The IRMA-2 study was started to evaluate the potential association between RI and cancer survival.
  • METHODS: Data were collected for cancer patients presenting at one of the 19 IRMA-2 centers in March 2005.
  • RESULTS: 4267 cancer patients (breast 1601, colorectal 575, lung 407, ovarian 269, prostate 224) with available data (aMDRD and follow-up) were included in the analysis.
  • CONCLUSIONS: IRMA-2 is the first large scale study reporting an association between RI and a reduced cancer survival.
  • Cancer patients with aMDRD<60 seemed to be more at risk of death for the following 2 years even in non metastatic patients.
  • IRMA-2 underlines that assessing, monitoring and managing renal function in cancer patients is crucial in order to prevent or at least minimise renal dysfunction because of its potential impact on survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963707.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Janus N, Oudard S, Beuzeboc P, Gligorov J, Ray-Coquard I, Morere J, Spano J, Pourrat X, Deray G, Launay-Vacher V: Prevalence of renal insufficiency in cancer patients: Data from the IRMA-2 study. J Clin Oncol; 2009 May 20;27(15_suppl):9559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of renal insufficiency in cancer patients: Data from the IRMA-2 study.
  • : 9559 Background: The IRMA-1 study reported the high prevalence of renal insufficiency (RI) in 4,684 cancer patients, with a glomerular filtration rate (GFR) <90 and <60 ml/min/1.73m<sup>2</sup> for 52.9% and 12.0%, respectively.
  • METHODS: Data were collected for cancer patients presenting at one of the 19 IRMA-2 centers in March 2005: type of tumour, sex, age, weight, serum creatinine (SCR), and anticancer drugs.
  • RESULTS: 4,945 patients (breast 1816, colorectal 747, lung 463, ovarian 294, prostate 251) were included in the IRMA-2 study.
  • CONCLUSIONS: The results of IRMA-2 and IRMA-1 confirm the high prevalence of RI in cancer patients, on 2 different cohorts of nearly 5,000 cancer patients each.
  • This underlines that estimating renal function in cancer patients is mandatory and that this highly frequent co-morbidity should be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kurbacher CM, Schmidt M, Kurbacher JA, Schäfer S, Arenz PN, Nagel WJ, Reinhold U: Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):e14544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VEGF inhibition may thus result in an improved anti-cancer immune response which may be further augmented by GM-CSF, a powerful stimulator of DC generation.
  • METHODS: 26 pts have been enrolled: epithelial ovarian cancer, n=12; breast cancer, n= 6; primary peritoneal carcinoma, n=3; hormone-refractory prostate cancer, n=2; miscellaneous, n=3.
  • RESULTS: Grade (G) 3-4 hypertension was seen in 3 pts, with 1 pt experiencing cerebral stroke 6 weeks after cessation of BEV+GM-CSF.
  • The objective response rate was 31% (1 CR, 7 PR, 10 SD, and 8 PD); the rate of pts benefiting was 69%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963617.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Koolen S, Witteveen PO, Garcia-Ribas I, Callies S, Andre V, Kronemeijer RH, Nol A, Beijnen JH, Voest EE, Schellens JH: Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No grade 3 or 4 toxicities were reported at dose-levels < 40 mg.
  • One pt with refractory prostate cancer presented a PSA CR as assessed by investigator.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961892.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Chiorean EG, Mahadevan D, Harris WB, Von Hoff DD, Younger AE, Rensvold DM, Shelton CF, Hennessy BT, Garlich JR, Ramanathan RK: Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LY294002 inhibits other kinases including mTOR, DNA-PK, PIM1, PLK1, and CK2, and induces oxidative stress in cancer cells independent of its PI3K inhibition.
  • No other grade 3/4 drug related toxicities have been reported.
  • Eleven pts showed stable disease for ≥ 8 wks, including durations of 20 wks for one GIST, 1 endometrial, and 1 prostate; 15 wks for 1 pancreatic; 11 wks for 2 GIST, 2 ovarian, and 1 CRC pt.
  • PD: Compared to baseline biopsy, we observed significant inhibition of pS6 by IHC in a tumor biopsy 20 hours after the 8<sup>th</sup> dose in a pancreatic cancer pt at 240 mg/m<sup>2</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961868.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M: Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types included: colorectal (8), non-small cell lung (NSCLC) (4), small cell lung (3), soft tissue sarcoma, (3), head and neck (2), prostate (2), and other (4).
  • Common C1 worst-grade drug related toxicities (CTC I/II % vs III/IV %): Hg (27/8), WBC (11/19), ANC (19/8), platelets (19/12), fatigue (15/8) insomnia (8/0), flushing (15//0), constipation (8/0), nausea (23/0), ALT elevation (12/0), hiccups (8/0).
  • Antitumor activity, assessed by development of PR and SD, was observed in NSCLC, SCLC, colon and bladder cancer.
  • This work was supported by R21-CA-123867 and Arno Therapeutics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Townsend AR, Millward M, Price T, Mainwaring P, Spencer A, Longenecker A, Palladino MA, Lloyd GK, Spear MA, Padrik P: Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol; 2009 May 20;27(15_suppl):3582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Gonzalez V, Velez M, Pedro E, Cruz C, Cotto M, Colon M, Romaguera J, Chevere-Mourino C, Delgado-Mateu LA, Tirado-Gomez M: Identification of supportive care needs in a sample of Puerto Rican cancer patients with the Supportive Care Needs Survey-34 (SCNS-34). J Clin Oncol; 2009 May 20;27(15_suppl):e20697

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of supportive care needs in a sample of Puerto Rican cancer patients with the Supportive Care Needs Survey-34 (SCNS-34).
  • : e20697 Background: The assessment of supportive care needs is important in the management of cancer patients.
  • The Supportive Care Needs Survey (SCNS-34) was administered to a population of Puerto Rican cancer patients to assess their perceived needs in five domains (psychological, health system and information, physical and daily living, patient care and support, and sexuality.
  • The most common malignancies were breast cancer (29 patients), gynecologic cancers (22 patients), prostate cancer (17 patients) and gastrointestinal cancers (14 patients).
  • Also, a diagnosis of breast cancer was a significant predictor of perceived needs in the health system and information domain (p=0.020).
  • The supportive care needs of Puerto Ricans cancer patients seem to be affected by age, gender, and cancer site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961745.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Vishnu P, Jasti P, Ding L, Heilbrun LK, Venkatramanamoorthy R, LoRusso PM, Heath EI: Retrospective study of phase I clinical trials participation in patients at least 65 years of age at Karmanos Cancer Institute (KCI), Wayne State University, Detroit, Michigan. J Clin Oncol; 2009 May 20;27(15_suppl):e20626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of phase I clinical trials participation in patients at least 65 years of age at Karmanos Cancer Institute (KCI), Wayne State University, Detroit, Michigan.
  • Colorectal (27%), lung (15%) and prostate (8%) were the 3 most common cancers.
  • The 3 most common Grade 3-4 toxicities were: 15% leucopenia, 11% electrolyte abnormalities, and 4% anemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961597.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Ibrahim NK, Wong L, Rosen L, Shan J: Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):1080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results.
  • DLT was defined as ≥ grade 3 drug-related adverse events (AE), ≥ grade 2 PT, or ≥ grade 3 aPTT.
  • RESULTS: Data are available for the first 20 pts enrolled (10 breast, 3 colorectal, 2 pancreatic, 1 each of hepatocellular carcinoma, head and neck, melanoma, mesothelioma, and prostate cancer).
  • All AEs were grade 1 or 2 and no dose relationship was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Frenkel M, Peterson N, Swint K, Cohen L: Integrative medicine consultation with cancer patients: Does it affect patients concerns and well-being? J Clin Oncol; 2009 May 20;27(15_suppl):e20581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative medicine consultation with cancer patients: Does it affect patients concerns and well-being?
  • : e20581 Background: Increased numbers of cancer patients are searching for additional options outside of their conventional medical care to improve their clinical outcome, quality of life, and overall wellbeing.
  • METHODS: Patients attending academic integrative medicine clinic evaluated their concerns and wellbeing using the Measure Yourself Concerns and Wellbeing (MYCaW) scale, a validated tool assessing outcome of complementary consultation for cancer patients.
  • RESULTS: Oncologists in the cancer center referred 197 patients for consultation about the integration of complementary medicine to their care.
  • The leading diagnosis was breast cancer followed by prostate cancer, but all major cancer diagnoses were represented.
  • CONCLUSIONS: Integrative medicine consultations for cancer patients appear to be a valuable service that addresses patients' main concerns and improves well being.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961208.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Oudard S, Janus N, Gligorov J, Beuzeboc P, Ray I, Morere J, Spano J, Pourrat X, Deray G, Launay-Vacher V: Renal function evolution in cancer patients. Results of the IRMA-2 study. J Clin Oncol; 2009 May 20;27(15_suppl):e20574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal function evolution in cancer patients. Results of the IRMA-2 study.
  • : e20574 Background: In 2007, the IRMA-1 study reported the high prevalence of renal insufficiency (RI) in cancer patients.
  • Because of this high frequency, the IRMA-2 study started to investigate the evolution of renal function in cancer patients.
  • METHODS: Data were collected for cancer patients presenting at one of the 19 IRMA-2 centers in March 2005.
  • RESULTS: 4945 cancer patients (breast 1816, colorectal 747, lung 463, ovarian 294, prostate 251) were included in 19 cancer centre in France.
  • CONCLUSIONS: IRMA-2 shows that renal function decreases rapidly in cancer patients with a loss in GFR of more than 3.5 mL/min/1.73m<sup>2</sup> per year.
  • This suggests that cancer patients are more exposed to a deterioration of renal function and that it should be closely monitored with at least a regular estimation of renal function, for instance every 6 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961111.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL: Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.
  • We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
  • METHODS: Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers.
  • Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
  • RESULTS: 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Mayer E, Baurain J, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart A: Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. J Clin Oncol; 2009 May 20;27(15_suppl):1011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088.
  • A phase II trial was performed in patients (pts) with ER+ and/or PR+ and/or HER-2-amplified progressive advanced breast cancer.
  • Subsequent to study initiation, dasatinib demonstrated similar efficacy with a lower incidence of key side-effects at 100 mg once daily in CML and prostate cancer.
  • RESULTS: Sixty-eight pts, 24 with HER-2-amplified and 44 with HER-2-normal, ER+ and/or PR+ disease, were treated.
  • All 9 controlled tumors were ER/PR+, 2 were also HER-2-amplified; thus, disease control rate was 19% in the 47 radiographically-evaluable pts with ER/PR+ disease.
  • Drug-related grade 3-4 AEs were reported in 37% of pts and comparable between doses, but related serious AEs were less frequent at 70 mg BID than 100 mg BID (16% vs 26%).
  • Grade 3-4 laboratory abnormalities were uncommon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960737.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Boccardo F: An open, randomized, multicentre, phase III trial comparing the efficacy of two tamoxifen (T) schedules in preventing gynecomastia (gy) induced by bicalutamide monotherapy (BM) in prostate cancer patients (pca pts). J Clin Oncol; 2009 May 20;27(15_suppl):e16080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open, randomized, multicentre, phase III trial comparing the efficacy of two tamoxifen (T) schedules in preventing gynecomastia (gy) induced by bicalutamide monotherapy (BM) in prostate cancer patients (pca pts).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963100.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Lo Re G, Boccalon M, Maruzzi D, Bortolus R, Lenardon O, Marus V, Rustici C, Tumolo S, Garbeglio A, Sulfaro S: A phase II noncomparative study of neoadjuvant (NA) chemohormone therapy (CHT), radical prostatectomy (RP), and postoperative radiotherapy (RT) in locally advanced (LA) high-risk prostate cancer (HRPC): A monoinstitutional 6-year experience with two NA CHT regimens. J Clin Oncol; 2009 May 20;27(15_suppl):e16091

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II noncomparative study of neoadjuvant (NA) chemohormone therapy (CHT), radical prostatectomy (RP), and postoperative radiotherapy (RT) in locally advanced (LA) high-risk prostate cancer (HRPC): A monoinstitutional 6-year experience with two NA CHT regimens.
  • : e16091 Background: HRPC criteria include stage T2b-T2c according to the AJCC classification, PSA ≥ 10 ng/ml, Gleason score (GS) 7-10 with 12, 6% 7-year cancer specific mortality rate (D'Amico AV, Cancer. 2006).
  • METHODS: Histological diagnosis of LA HRPC (T2b-T4), GS > 8, PSA > 10 ng/ml, age < 65 years, PS 0-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Morris MJ, Pandit-Taskar N, Stephenson RD, Hong C, Slovin SF, Rathkopf D, Solit D, Carrasquillo J, Larson S, Scher HI: Phase I/II study of docetaxel and &lt;sup&gt;153&lt;/sup&gt;Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort. J Clin Oncol; 2009 May 20;27(15_suppl):5057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel and <sup>153</sup>Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort.
  • Pts with an ANC of grade 0-1 and platelet count of > 100,000/mm<sup>3</sup> at the end of cycle 1 received additional cycles until progression or toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Sinibaldi VJ, Carducci MA, Moore-Cooper S, George B, Denmeade S, Drake CG, Walczak J, Pili R, Zahurak ML, Eisenberger MA: A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M&lt;sub&gt;0&lt;/sub&gt;) after local treatment (LT). J Clin Oncol; 2009 May 20;27(15_suppl):5130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M<sub>0</sub>) after local treatment (LT).
  • Data coordination infrastructure is supported by the Prostate Cancer Foundation and The James Stine research fund.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964411.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Veverka KA, Malkowicz B, Smith M, Morton RA, Steiner MS: The effect of toremifene citrate on BMD in men on ADT: A phase III clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):5055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of toremifene citrate on BMD in men on ADT: A phase III clinical trial.
  • In a recently completed two-year randomized controlled trial of 1382 men, toremifene increased BMD and decreased vertebral fracture incidence in men receiving ADT for prostate cancer.
  • METHODS: We conducted a randomized double blind placebo controlled trial in 1382 men with histologically confirmed prostate cancer on ADT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962973.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Senior K: Defining biochemical failure in prostate cancer. Lancet Oncol; 2007 Dec;8(12):1059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining biochemical failure in prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28581420.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Halabi S, Sartor O, Petrylak D, Sternberg CN, Witjes JA, Noursalehi M, McKearn TJ, George MJ: Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964451.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Sartor AO, Petrylak D, Sternberg C, Witjes F, Halabi S, Berry W, Petrone M, McKearn T, Noursalehi M, George M: Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. J Clin Oncol; 2009 May 20;27(15_suppl):5148

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964442.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Song W, Schaly B, Bauman G, Battista J, Van Dyk J: Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. Med Phys; 2005 Jul;32(7Part1):2193-2203

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate.
  • The goal of this work was to evaluate the efficacy of various image-guided adaptive radiation therapy (IGART) techniques to deliver and escalate dose to the prostate in the presence of geometric uncertainties.
  • Five prostate patients with 15-16 treatment CT studies each were retrospectively analyzed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28493587.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed radiography / Computed tomography / Conformal radiation treatment / Diseases / Dosimetry / Effects of ionizing radiation on biological systems / Image guided radiation therapy / Intensity modulated radiation therapy / Medical imaging / Probability theory / Radiation treatment / Tissues / Treatment strategy / Ultrasonography / Verification / biological effects of ionising radiation / biological organs / biomedical imaging / cancer / computerised tomography / dosimetry / image-guided adaptive radiation therapy / iso-NTCP dose escalation / laser applications in medicine / normal tissue complication probability / probability / prostate cancer / radiation therapy / tumor control probability / tumours
  •  go-up   go-down


90. Lubaroff DM, Vaena DA, Williams RD, Joudi FN, Smith MC, Zehr PS, Eastman J, Griffith K, Madsen TM, Johnson K: A phase II trial of an adenovirus/PSA vaccine for prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of an adenovirus/PSA vaccine for prostate cancer.
  • We are conducting a phase II clinical trial with two separate protocols for patients with recurrent or hormone-refractory prostate cancer assessing toxicity, immune responses, and change in PSA levels.
  • METHODS: In Protocol 1 men with recurrent prostate cancer after definitive initial treatment were randomized to arm A (vaccine injection alone at days 0, 30, and 60) or arm B (vaccine injection 14 days after initiation of androgen deprivation therapy).
  • 11% have stable serum prostatic acid phosphatase (PAP) levels, 56% have decreased levels, and 33% have increased levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962013.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Men K, Dai J, Li M, Zhang Y: A method to correct the influence of carbon fiber couchtop and patient positioning device on image quality of cone beam CT. Med Phys; 2010 Jun;37(6Part1):2466-2472

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The performance of the correction method was evaluated using the CBCT images of a Catphan 500 phantom, a head-and-neck cancer patient, and a prostate cancer patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512981.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Carbon / Computed tomography / Cone beam computed tomography / Medical X-ray imaging / Medical image noise / Medical image quality / Medical image reconstruction / Medical image spatial resolution / Medical imaging / Noise / Spatial resolution / X-ray imaging / biological organs / biomedical equipment / cancer / carbon fibres / computerised tomography / cone beam computed tomography / couchtop / image denoising / image quality / image resolution / medical image processing / phantoms / positioning device
  •  go-up   go-down


92. Trock B, Han M, Humphreys EB, Partin AW, Eisenberger MA, Walsh PC: Survival following early hormone therapy for men with rapid PSA doubling time within 2 years following radical prostatectomy. J Clin Oncol; 2009 May 20;27(15_suppl):5065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: With median follow-up of 6 years after recurrence and 9 years after RP, there were 143 deaths (29%), including 105 from prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Mustian KM, Fisher S, Adams J, Janelsins M, Palesh O, Darling T, Peppone L, Heckler C, Williams J, Morrow G: Cytokine-mediated changes associated with improvements in cancer-related fatigue induced by exercise: Results from a randomized pilot study of cancer patients receiving radiotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):9632

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine-mediated changes associated with improvements in cancer-related fatigue induced by exercise: Results from a randomized pilot study of cancer patients receiving radiotherapy.
  • : 9632 Background: Radiation therapy (RTH) results in dysregulated inflammatory profiles which increase cancer-related fatigue (CRF).
  • METHODS: Breast and prostate cancer patients (N=38; mean age=57; 71% breast/female), beginning at least 28 sessions of RTH, were randomized to a 4wk HBEX (7 days/wk) or standard care (SC; RTH with no exercise).
  • Future phase III randomized controlled trials are needed with larger samples to fully investigate these relationships.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963926.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Lasch KE, Jernigan KA, Scott JA, Piault-Louis E: Interviews with cancer fatigue patients. J Clin Oncol; 2009 May 20;27(15_suppl):e17577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interviews with cancer fatigue patients.
  • : e17577 Background: Approximately 90% of patients diagnosed with cancer experience fatigue associated with the effects of treatment and/or cancer itself.
  • Despite its high prevalence and negative impact on patients' lives, there is no consensus on a clinical definition of cancer-related fatigue (CF).
  • A multi-disciplinary research consortium is developing a conceptual model of CF based on 120 qualitative interviews with cancer patients varying by cancer type and stage.
  • METHODS: Five cancer patients with self-reported CF were purposively sampled and interviewed between September 2007 and March 2008 by a trained interviewer to discuss their CF experiences.
  • RESULTS: Patients were diagnosed with cancer on average 3.5 years ago among the following primary sites: breast (n = 2), lung, colorectal, and prostate/liver.
  • Patients described CF as a general lack of ability to do anything, a child-like regression, and indicated that current "tiredness" differed from pre-diagnosis tiredness.
  • CONCLUSIONS: Patients' experience with CF differs from pre-diagnosis tiredness in terms of intensity, duration, onset, and impact.
  • Further research with patients with different cancer types and stages is needed to develop a comprehensive conceptualization and measurement of CF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963916.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Christiansen CF, Johansen MB, Christensen S, Langeberg W, Fryzek JP, Toft Sørensen H: Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark. J Clin Oncol; 2009 May 20;27(15_suppl):9570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark.
  • : 9570 Background: Although cancer patients may be at increased risk for acute kidney injury (AKI), which could then reduce their likelihood of receiving optimal therapeutic management and supportive care, the occurrence of AKI among newly diagnosed cancer patients has not been well-described.
  • Therefore, we examined the incidence of AKI within the first year after cancer diagnosis to estimate the magnitude of this risk and better understand which patients are at greatest risk.
  • METHODS: Using the population-based Danish Cancer Registry, we conducted a retrospective cohort study of 4,427 men and women from North Jutland, Denmark (population 500,000) diagnosed with cancer from 2002 to 2003 (non-melanoma skin cancer excluded).
  • Baseline sCr was defined as the lowest sCr in the year before cancer diagnosis.
  • We compared this value to the highest sCr on record during the first year following cancer diagnosis to identify those who experienced an AKI.
  • RESULTS: Median age for the cohort was 68.6 years, 50.9% were men, and the most common cancer sites were lung (14.2%), breast (13.7%), prostate (9.8%), colon (9.6%), rectum (5.1%), and bladder (6.3%).
  • Incidence was highest among patients aged 80 years or older (531 per 1,000 person-years, 95% CI 464-606) and in those with cancer of the liver (1,221, 95%CI 676-2,205), pancreas (1,472, 95%CI 1,130-1,917), or kidney (1,254, 95%CI 974-1,616), or with multiple myeloma (855, 95%CI 538-1,356).
  • Our study showed that over 20% of cancer patients may experience acute kidney injury in the first year after diagnosis.
  • Older patients and those with cancer of the liver, pancreas, or kidney, or with multiple myeloma are especially at risk for AKI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963659.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Passalacqua R, Brighenti M, Naldi N, Potenzoni D, Monica B, Fumagalli M, Lazzarelli S, Caminiti C: Long-term effects of a program of bladder preservation using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Analysis of biologic predictive factors and health-related quality of life (QOL). J Clin Oncol; 2009 May 20;27(15_suppl):e16014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of a program of bladder preservation using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Analysis of biologic predictive factors and health-related quality of life (QOL).
  • The Expanded Prostate Cancer Index Composite (EPIC) scores for urinary function, (especially storage, voiding symptoms and bowel function) was used to explore QOL in bladder preserved and compared with a group of matched patients treated by radical cystectomy only.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Ferreira Filho AF, Wunder AP, da Silva DL, Slomka L, Machado MW, Dos Santos MP, Graeff S, Freitas D, Friedrich A: Analysis of resilience scores in a cohort of solid tumors ambulatory cancer patients in chemotherapy treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e20736

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of resilience scores in a cohort of solid tumors ambulatory cancer patients in chemotherapy treatment.
  • Very scanty data exists regarding its quantification and distribution in cancer patients.
  • The objective of this study is to evaluate and describe resilience scores in a population of ambulatory solid tumors cancer patients receiving chemotherapy treatment.
  • During the year 2008, this scale was applied to 48 ambulatory solid tumor cancer patients in chemotherapy treatment at Oncosinos / Hospital Regina in Novo Hamburgo, Brazil.
  • The most common cancer types were: breast (48%), colo-rectal (21%) and prostate (8%).
  • Stage III cancer was present in 40% and stages I and II in 13% of patients.
  • No statistical differences in the mean resillience scores were detected between groups of patients as defined by: sex (P=0.11), age > or < 50 years (P=0.9), cancer type (P= 0.78), disease staging (P= 0.9), or the chemotherapy treatment intention, if palliative or curative (P=0.91).
  • Our results suggest that the total resillience score is an intrinsic individual characteristic that is independent of cancer stage, cancer type, age and sex of the patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962006.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Vidal M, Ferrer A, Serrano S, Tobeña M, Pajares I, Lopez D, Millastre E, Ruiz-Echarri M, Lambea J, Tres A: Fever in cancer patients as a cause of attendance in emergency room. J Clin Oncol; 2009 May 20;27(15_suppl):e20706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fever in cancer patients as a cause of attendance in emergency room.
  • Cancer patients frequently experience fever.
  • Nearly two-thirds of the cases of fever in patients with prolonged neutropenia could be attributed to infection, a major cause of morbidity in cancer patients.
  • PURPOSE: The aim of our study is to evaluate the prevalence of cancer patients who were attended in the emergency room for fever, the diagnosis and clinical management.
  • METHODS: From October 2007 to October 2008, 560 cancer patients were seen in the emergency department of the University Hospital of Zaragoza.
  • Cancer tumor type, 35 had lung cancer (35.7%), 14 had breast cancer (14.3%), 9 had colorectal cancer (9.2%), 9 had urothelial cancer (9.2%), 5 had head neck cancer (5.1%), 5 had pancreatic cancer (5.1%), 3 had esophageal cancer (3%), 2 had prostate cancer (2%), and 14,3% had other neoplasm.
  • By diagnosis: 23 patients (23,46%) were diagnosed of febrile neutropenia, and 19 of them (82,6%) required admission to the hospital.
  • CONCLUSIONS: Fever in cancer patients remains a challenge, and the differentiation between infectious and non-infectious causes at onset of fever is very difficult.
  • Infection in the immunocompromised host is a serious clinical situation due to high morbimortality and is one of the most frequent complications in the patient with cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Ninan JA, Bailey H, Kolesar J, Marnocha R, Eickhoff J, Wright J, Espinoza-Delgado I, Alberti D, Wilding G, Schelman W: A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types include: Prostate (1), Colorectal (3), Pancreatic (6), Sarcoma (7), Biliary (1), Thymus (1), GIST (2), Mesothelioma (1), ovarian (1), Neuroendocrine (1), Lung (1), Head and Neck (1), Breast (2), and Cervical (1).
  • Grade 3-4 toxicities possibly related to SAHA at any dose level were as follows: thrombocytopenia (5), fatigue (3), increased ALT (1), elevated INR (1), anemia, (1), hypotension (1), diarrhea (3), anorexia (1), dizziness (1), nausea/vomiting (1), and hypoalbuminemia (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961857.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Isambert N, Spitaleri G, Fumoleau P, Noberasco C, Ramazeilles C, Chadjaa M, Bolloni L, De Braud F: A phase I dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion twice-weekly during a 3-week cycle in patients (pts) with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Main tumor types: ovary, lung, breast, colon and prostate.
  • DLT was seen in 2 pts at 1000 mg/m<sup>2</sup> dose level: one patient had febrile neutropenia associated with Grade 3 mucositis and the second patient had Grade 3 neutropenia, which caused a treatment delay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961849.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement